Neso Tablet (375 mg/20 mg): Each enteric coated tablet contains Naproxen BP 375 mg & Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.
Neso Tablet (500 mg/20 mg): Each enteric coated tablet contains Naproxen BP 500 mg & Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.
Naproxen is a NSAID with analgesic and antipyretic properties. The mechanism of action of Naproxen is like that of other NSAIDs, related to prostaglandin synthetase inhibition. Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
Neso Tablet is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAIDs-associated gastric ulcers.
Several studies have shown no interaction between the two components Naproxen and Esomeprazole. NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. Probenecid increases Naproxen anion plasma levels and extends its plasma half-life significantly. Co-administration of oral contraceptives, diazepam, phenytoin or quinidine does not seem to change the pharmacokinetic profile of Esomeprazole.
This combination is contraindicated in patients with known hypersensitivity to Naproxen, Esomeprazole Magnesium or to any of the excipients. This combination is contraindicated in patients who have experienced asthma, urticaria or allergic reactions after taking aspirin or other NSAIDs. This combination is also contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery and in patients in the late stage of pregnancy.
The adverse effects reported with this combination may include gastrointestinal disorders like dyspepsia, diarrhea, nausea, flatulence, abdominal pain etc.
Pregnancy: There are no adequate and well-controlled studies of Netarsudil ophthalmic solution in pregnant women to inform any drug-associated risk. However, systemic exposure to Netarsudil from ocular administration is low.
Lactation: There are no data on the presence of Netarsudil in human milk, the effects on the breastfed infant, or the effects on milk production.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 18 years have not been established.
Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Store below 30 C, protect from light. Keep out of the reach of children